Rare Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with an advanced solid tumour (confirmed by laboratory tissue analysis) and are suitable candidates for drug-based cancer treatment.
- People who have stored tumour tissue samples (a specific type called FFPE archived tissue) available for molecular testing.
- People who are 18 years of age or older.
- People whose general health and ability to carry out daily activities is rated at a good level (scored 0 or 1 on a standard medical scale called the ECOG scale — confirm with trial site if unsure what this means for a specific situation).
- People who have a life expectancy of more than 6 months, as assessed by their doctor.
- People whose organs (such as kidneys, liver, and heart) are functioning at an adequate level.
- People who have read, understood, and signed a consent form agreeing to take part in the trial.
Who may not be able to join:
- People who have already received more than 2 rounds of chemotherapy-type treatment for their advanced or spreading cancer — though an exception may apply for those being considered specifically for the Phase I portion of the trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philippe Bedard, MD, Princess Margaret Hospital, Canada
Phone: 416-946-4501
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients included in a province-wide registry of NGS panel-based testing results; Change in use of NGS panel-based testing in Ontario clinical genetic testing laboratories; Number of patients included in province-wide repository of genomically-characterized tumour tissue and blood samples and their utilization rates for future research; Change in rates of genomics based clinical research in Ontario; Utilization rates of province-wide genomically-characterized and clinically-annotated patient base in enrollment into specific research initiatives; Utilization rates of molecular profili...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.